7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
macrophages and T cells ... involvement - seeding ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
macrophages and T cells ... involvement - seeding ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
Leukemias Overview: ALL, CML, AML, APML, CLL

Acute leukemias > 20% blasts in the peripheral blood smear
Tyrosine Kinase activity ... develop leukostasis syndrome ... • Tumor lysis syndrome ... #Leukemia #Hematology ... #Oncology #Diagnosis
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
unusual bruising or bleeding ... are caused by bleeding ... factor (GCSF) treatments ... #diagnosis #hematology ... #oncology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
Constitutional Syndromes ... ecchymoses, mucosal bleeding ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #hematology #diagnosis
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... Imaging: CXR- pulmonary ... diagnosis #management #hematology ... #oncology
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Disease: • 10%-15% Pulmonary ... , INC risk PE, Pulmonary ... Nephrogenic DI Hematologic ... Adenocarcinoma Treatment ... muscarinic agonists • Active